Výsledky vyhledávání - Shebl, Amgad

  • Zobrazuji výsledky 1 - 6 z 6
Upřesnit hledání
  1. 1
    Anti‐A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital‐based cohort study

    Anti‐A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital‐based cohort study Autor Wallenhorst, Christopher, Patel, Ami, Shebl, Amgad, Hubsch, Alphonse, Simon, Toby L., Martinez, Carlos

    Vydáno 2020
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Impact of screening and exclusion of high anti‐A titer donors on the risk of hemolytic anemia with intravenous immunoglobulin treatment: A hospital‐based cohort study in the US

    Impact of screening and exclusion of high anti‐A titer donors on the risk of hemolytic anemia with intravenous immunoglobulin treatment: A hospital‐based cohort study in the US Autor Martinez, Carlos, Watson, Douglas J., Shebl, Amgad, Wallenhorst, Christopher, Hubsch, Alphonse, Simon, Toby L.

    Vydáno 2017
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis of spontaneous adverse event reports

    Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis... Autor Shebl, Amgad, Gabriel, Susie, Van Dinther, Kristy, Hubsch, Alphonse, Lawo, John‐Philip, Hoefferer, Liane, Welsh, Susan

    Vydáno 2020
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme

    Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme Autor Greulich, Timm, Chlumsky, Jan, Wencker, Marion, Vit, Oliver, Fries, Michael, Chung, Thomas, Shebl, Amgad, Vogelmeier, Claus, Chapman, Kenneth R., McElvaney, Noel G.

    Vydáno 2018
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)

    Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA stu... Autor Léger, Jean-Marc, De Bleecker, Jan L, Sommer, Claudia, Robberecht, Wim, Saarela, Mika, Kamienowski, Jerzy, Stelmasiak, Zbigniew, Mielke, Orell, Tackenberg, Björn, Shebl, Amgad, Bauhofer, Artur, Zenker, Othmar, Merkies, Ingemar S J

    Vydáno 2013
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study

    Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneur... Autor Mielke, Orell, Bril, Vera, Cornblath, David R., Lawo, John‐Philip, van Geloven, Nan, Hartung, Hans‐Peter, Lewis, Richard A., Merkies, Ingemar S.J., Sobue, Gen, Durn, Billie, Shebl, Amgad, van Schaik, Ivo N.

    Vydáno 2019
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: